Roslyn Dillon

Roslyn Dillon currently serves as the Director of Program and Portfolio Management at Altos Labs, a position held since September 2022. Prior to this, Roslyn was the Product Development Lead at DiscernDx from January 2019 to August 2022, where responsibilities included providing business strategy and technical guidance for a mass spec-based clinical assay. Roslyn also managed product development at Applied Proteomics, Inc. as the Director of Product Development from January 2012 to December 2018, overseeing mass spectrometry-based biomarker discovery and the development of colorectal cancer assays. Earlier in the career, Roslyn worked as a Senior Scientist in Research & Development focusing on colorectal cancer biomarker discovery and contributed to preclinical pharmacology at Pfizer from March 1999 to September 2011, supporting IND submissions for various Oncology drugs. Roslyn began the professional journey as an Associate Scientist at Millennium Pharmaceuticals from September 1995 to February 1999. Educational background includes a B.Sc. (Hons) from University College Dublin, completed in 1995.